Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab pilot study of Lp(a) metabolism in statin-treated adults with inherited high lipoprotein(a)
ACTRN12617000401358Phase 2Completed
- Sponsor
- Linear Clinical Research
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alirocumab in cardiac morbidity and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Linear Clinical Research. Primary endpoint: Change in plasma lipoprotein(a) level. Started Jan 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on ACTRN12617000401358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000401358.